JU Jensen has a background in sepsis, respiratory failure and biomarker research and has lead several multicentre randomized controlled trials in intensive care units across Europe and USA. Currently, Study Director of the Cooling And Surviving Septic shock trial (CASS-trial), a study to test the hypothesis of whether mild induced hypothermia can improve survival in septic shock patients by improving tissue perfusion, preserving mitochondrial function.

Apart from generating and testing hypotheses regarding antibiotic strategies and other ways of infection control, Dr. Jensen has lead several studies of endothelial dysfunction, coagulopathies in sepsis, renal dysfunction in critical illness and pathophysiological studies. Dr. Jensen has been awarded the 2013 Hellsing prize from the Nordic Society for Clinical Biochemistry for his work on the relation between biomarker performance and clinical effects.

He has supervised two successfully defended PhD´s and is currently supervising 3 phd students. 43 publications. 827 citations. H-index 10.

International collaborators include the Outcomes Research at Cleveland Clinic, Ohio, USA and ICU research at the Academic Medical Centre (AMC) in Amsterdam

Sepsis; Acute Respiratory Failure; Biomarkers; COPD;

Randomized trial on mild induced hypothermia in Septic Shock

Liver failure in Sepsis

Genomic host characteristics in Sepsis and clinical consequences

Individualized corticosteroid therapy in COPD

The Role of chronic colonisation of the airways in COPD

2016: ERS congress participation arranged by Roche pharmaceuticals.

2011-2016: Discount on cooling devices for an investigator-initated and driven RCT. Companies: ZOLL, BARD and EMCOOLS.